Spots Global Cancer Trial Database for myelodysplastic syndromes
Every month we try and update this database with for myelodysplastic syndromes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole | NCT03434704 | Transplant-Rela... Leukemia, Acute Myelodysplastic... Graft Vs Host D... Fungal Infectio... | Conditioning tr... PBSC graft GvHD prophylaxi... Primary antifun... | 18 Years - | IRCCS San Raffaele | |
| Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome | NCT00003171 | Leukemia Myelodysplastic... | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Institut Paoli Calmettes Myelodysplastic Syndromes Database | NCT03275480 | Myelodysplastic... | 18 Years - | Institut Paoli-Calmettes | ||
| Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes | NCT02240706 | Myelodysplastic... | Best Supportive... BI 836858 | 18 Years - | Boehringer Ingelheim | |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | NCT05365035 | Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Venetoclax Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | NCT06315309 | GVHD,Acute Acute Leukemia Myelodysplastic... Myeloproliferat... | ATG Combined wi... | 18 Years - 60 Years | University of Alabama at Birmingham | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00005598 | Myelodysplastic... | amifostine trih... azacitidine | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) | NCT02243124 | Myelodysplastic... | cenersen Dexamethasone | 18 Years - 95 Years | Eleos, Inc. | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | NCT03291444 | Leukemia, Acute... Leukemia, Acute... Myelodysplastic... | Chimeric antige... peptide specifi... | 18 Years - 80 Years | Zhujiang Hospital | |
| Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants | NCT01488253 | Acute Leukemia ... Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Sirolimus Tacrolimus | 20 Years - 60 Years | The Korean Society of Blood and Marrow Transplantation | |
| AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | NCT00396968 | Acute Myelogeno... Myelodysplastic... | AMD3100 Allogeneic Stem... | 18 Years - 60 Years | Sanofi | |
| Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer | NCT00002742 | Chronic Myelopr... Infection Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | amphotericin B ... nystatin | 2 Years - | National Cancer Institute (NCI) | |
| Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients | NCT03318159 | Aplastic Anemia Myelodysplastic... Fungal Infectio... | Posaconazole | 18 Years - 75 Years | Seoul National University Hospital | |
| Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome | NCT00003123 | Myelodysplastic... | amifostine trih... | 17 Years - | National Cancer Institute (NCI) | |
| A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome | NCT06304103 | Myelodysplastic... | AND017 | 18 Years - 75 Years | Kind Pharmaceuticals LLC | |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00003602 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin mitoxantrone hy... | 55 Years - | National Cancer Institute (NCI) | |
| A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT05140811 | Acute Myeloid L... Myelodysplastic... | IMM01 Azacitidine | 18 Years - | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies | NCT01943851 | Neoplasms | GSK525762 | 18 Years - | GlaxoSmithKline | |
| Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome | NCT00017550 | Myelodysplastic... | anti-thymocyte ... | 18 Years - 120 Years | Sanofi | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Tipifarnib in Subjects With Myelodysplastic Syndromes | NCT02779777 | Myelodysplastic... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Inqovi Maintenance Therapy in Myeloid Neoplasms | NCT04980404 | Myelodysplastic... Chronic Myelomo... Stem Cell Leuke... | Inqovi | 18 Years - | Massachusetts General Hospital | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT00720850 | Myelodysplastic... Acute Myelogeno... | lenalidomide | 18 Years - | Technische Universität Dresden | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) | NCT05568225 | Very Low Risk, ... | Etavopivat | 18 Years - | Novo Nordisk A/S | |
| Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes | NCT01302106 | Myelodysplastic... | Clofarabine plu... | 55 Years - 80 Years | Fondazione Italiana Sindromi Mielodisplastiche-ETS | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment | NCT05063591 | Hematologic Mal... Myelodysplastic... Acute Myeloid L... Lymphoma Leukemia Myeloma | Transfusion sup... | 18 Years - | Brown University | |
| Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies | NCT05588154 | Myelodysplastic... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | NCT04893915 | Relapsed Acute ... Refractory Acut... Myelodysplastic... | Cytokine-induce... Fludarabine Cyclophosphamid... Donor Leukapher... Interleukin-2 | 18 Years - | Washington University School of Medicine | |
| Identifying Characteristics of Bone Marrow Failure Syndromes | NCT00315419 | Bone Marrow Fai... Anemia, Aplasti... Myelodysplastic... Hemoglobinuria,... Red-Cell Aplasi... Purpura, Thromb... Leukemia, Lymph... | 11 Years - | Office of Rare Diseases (ORD) | ||
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | NCT02489929 | Myeloid Leukemi... Myelodysplastic... | blood samples azacytidine | 18 Years - 85 Years | Assistance Publique Hopitaux De Marseille | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) | NCT03057990 | Myelodysplastic... | Pyrimethamine | 18 Years - | Montefiore Medical Center | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome | NCT04969367 | Myelodysplastic... | Medical Device ... Biospecimen Col... Questionnaire A... Quality-of-Life... | 18 Years - | Thomas Jefferson University | |
| Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | NCT00303719 | Kidney Cancer Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... cyclosporine fludarabine mycophenolate m... stem cell trans... total body irra... filgrastim | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes | NCT03446638 | Myelodysplastic... | FDA-approved dr... FLAG induction 7 + 3 induction Low-dose cytara... Supportive care... Computational b... | 18 Years - 99 Years | University of Florida | |
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | NCT04543305 | Multiple Myelom... Acute Myeloid L... Non Hodgkin Lym... Myelodysplastic... | PRT1419 | 18 Years - | Prelude Therapeutics | |
| Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | NCT00451048 | Chronic Myelomo... de Novo Myelody... Myelodysplastic... Secondary Myelo... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes | NCT01381809 | Myelodysplastic... | Group 2: Placeb... Group 1: Epoeti... | 18 Years - | Janssen-Cilag International NV | |
| Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome | NCT00230178 | Tumor Lysis Syn... Cancer Hyperuricemia | Rasburicase (SR... Allopurinol | 18 Years - | Sanofi | |
| Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant | NCT03961919 | Acute Myeloid L... Myelodysplastic... Transplant-Rela... | Fludarabine ARA-C Treosulfan Peripheral Bloo... | 65 Years - | IRCCS San Raffaele | |
| CD34 Selection Using the Automated CliniMACS Prodigy | NCT06047886 | AML ALL Lymphoid Malign... Myelodysplastic... CML Primary Myelofi... | Infusion of CD3... | 4 Weeks - 75 Years | University of Alabama at Birmingham | |
| A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | NCT03886662 | Myelodysplastic... | LB-100 | 18 Years - | Lixte Biotechnology Holdings, Inc. | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | NCT02689622 | Myelodysplastic... | research of dis... research of com... physical perfor... | 70 Years - | University Hospital, Toulouse | |
| Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | NCT00034684 | Leukemia Myelodysplastic... Leukemia, Myelo... Blast Crisis Leukemia, Lymph... | Farnesyl Protei... | 18 Years - | Merck Sharp & Dohme LLC | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes | NCT00398047 | Leukemia Myelodysplastic... | Azacitadine and... | - 120 Years | Wake Forest University Health Sciences | |
| PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes | NCT06091267 | Myelodysplastic... | IV Decitabine Decitabine and ... only Decitabine... | 18 Years - | Otsuka Beijing Research Institute | |
| An European Platform for Translational Research in Myelodysplastic Syndromes | NCT04174547 | Myelodysplastic... | 18 Years - | Istituto Clinico Humanitas | ||
| MK0457 in Patients With Leukemia (0457-003) | NCT00111683 | Chronic Myeloge... Lymphocytic Leu... Myelodysplastic... Myelogenous Leu... | MK0457 | 18 Years - | Merck Sharp & Dohme LLC | |
| CyFluATG in Lower Risk MDS | NCT06098326 | Myelodysplastic... | cyclophosphamid... | 18 Years - 70 Years | Asan Medical Center | |
| Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome | NCT00004208 | Myelodysplastic... | ATG + CSA Supportive care | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| Gemtuzumab in Treating Patients With Myelodysplastic Syndrome | NCT00022321 | Myelodysplastic... | gemtuzumab ozog... | 18 Years - | National Cancer Institute (NCI) | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Survey on QUality of Life In myeloDisplasia (SQUID) | NCT00967564 | Myelodysplastic... | epidemiologic s... | 18 Years - | Janssen-Cilag S.p.A. | |
| Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00003790 | Leukemia Myelodysplastic... | polymerase chai... flow cytometry | - 21 Years | Children's Oncology Group | |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | NCT00571662 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplastic... Multiple Myelom... Non-Hodgkins Ly... Hodgkins Diseas... Peripheral T-ce... | Pentostatin Total-body irra... Cyclosporine A ... Mycophenolate M... G-CSF | 19 Years - 75 Years | University of Nebraska | |
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01362140 | MDS | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | NCT03810196 | Acute Leukemia Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Mixed Lineage L... Lymphoblastic L... Burkitt Lymphom... Juvenile Myelom... | CliniMACS Cell ... | - 25 Years | Children's Hospital of Philadelphia | |
| A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT02308761 | Acute Myeloid L... Myelodysplastic... | RO6870810 | 18 Years - | Hoffmann-La Roche | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes | NCT00064974 | Myelodysplastic... | CC-5013 | 18 Years - | Celgene | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia | NCT00607997 | Leukemia Acute Disease Acute Myeloid L... Nonlymphocytic ... Myelodysplastic... | vosaroxin | 60 Years - | Sunesis Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
